Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lisaftoclax · 5 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| Lisaftoclax (APG-2575) | DRUG | QD, oral administration. |
| Azacitidine Injection | DRUG | QD, hypodermic or intravenous injection. |
| Placebo | OTHER | QD, oral administration. |
| Acalabrutinib | DRUG | BID, oral administration, every 28 days for a dosing cycle. |
| Fludarabine | DRUG | Every 28 days for a treatment cycle, administration of 6 cycles. |
| Cyclophosphamide，CTX | DRUG | Every 28 days for a treatment cycle, administration of 6 cycles. |
| Rituximab | DRUG | Every 28 days for a treatment cycle, administration of 6 cycles. |
| Chlorambucil | DRUG | Every 28 days for a treatment cycle, administration of 6 cycles. |
| lisaftoclax +BTK inhibitor | DRUG | lisaftolax + BTK inhibitor |
| BTK inhibitor | DRUG | BTK inhibitor |
| Reduced-dose HHT | DRUG | 1mg IV QD on Days 1-14 (28-day cycle). |
| standard-dose HHT | DRUG | 2mg/m\^2 IV QD on Days 1-7 (28-day cycle). |
| Azacitidine | DRUG | 75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle). |
| olverembatinib | DRUG | orally, with meals, QOD, every 28 days as a cycle. |
| Lisaftoclax | DRUG | Lisaftoclax investigation drug in ramp up dosing |